CVC Capital Partners VIII to Acquire Majority Stake in Rayner
CVC Capital Partners VIII announced that it has agreed to acquire a majority interest in Rayner, the global ophthalmology business from UK-based private equity firm Phoenix Equity Partners.
Terms of the deal were not disclosed.
The transaction is expected to close in the third quarter of 2021, subject to customary closing conditions and receipt of required regulatory approvals.
Worthing, UK-based Rayner is a manufacturer and developer of IOLs and associated pharmaceuticals. Rayner, which developed the world’s first IOL in 1949, now makes IOLs and other products available to about 300,000 patients in over 80 countries through its subsidiaries and distribution networks.
“Rayner is a pioneer in the ophthalmology sector and is globally renowned. We are delighted to be backing this outstanding management team, led by the CEO Tim Clover, in accelerating the international expansion of the business,” Cathrin Petty, Managing Partner and Global Head of Healthcare at CVC, said in a company news release. “This is a wonderful example of UK technology innovation and manufacturing excellence that with the support of CVC’s global network we aspire to turn into a global champion.”
“With CVC’s backing and working in partnership with the company’s management team, Rayner will pursue a strategy focused on driving both organic and inorganic growth, while further enhancing Rayner’s reputation for innovation and product excellence,” Rayner stated in the news release. “Benefitting from CVC’s international reach and experience of the health care sector, including investments such as Sebia, Theramex and Recordati, and recent agreements to invest in Cooper, System C, MedRisk and ExamWorks, Rayner is poised to continue its growth as a global operator as demand for its broad suite of products and services in ophthalmology continues to grow.”
“Having recently tripled our manufacturing capacity and strengthened our R&D capability, we are primed to embark on our next phase of growth and improve outcomes for even more patients with our world-class implants and treatments for a broad range of ophthalmic conditions,” Tim Clover, CEO of Rayner, said in the news release. “With its extensive healthcare experience, CVC understands our business and supports our ambition to become an international ophthalmology leader.”
Kevin Keck, Partner at Phoenix Equity Partners, said: “Rayner is a great British success story, and it has been fantastic to have been able to play a part in that over the past 4 years. Tim and his team have worked tirelessly to build on the company’s fantastic track record and ensure it is well placed to continue its rapid growth in the years to come. We wish them all the best for the next stage of their journey.”
Cathrin Petty and Phil Robinson will represent CVC on Rayner’s board.